INTELLIGENT ONCOLOGY
choose a different vision
Recent Releases
CHOSA Oncology Presented at Aktiedagarna Stockholm
CHOSA Oncology presented its precision medicine approach to cancer treatment at Aktiedagarna (11 June 2025), highlighting our innovative strategies and upcoming milestones.
CHOSA Files Patent for Platinum-Immunotherapy Combination Predictor
New PCT application expands Platin-DRP® to predict patient response to platinum chemotherapy and PD-1/PD-L1 immunotherapy combinations (25 June 2025).
CHOSA Extends SPLENDOUR Study Timeline
CHOSA extends SPLENDOUR study timeline with ETOP to Q3 2025 to include additional high-quality biopsies (01 July 2025).We provide a safe and more effective solution for patients in need of platin-treatment
Drug Response Predictor
Discover the future of cancer treatment with DRP® — the first-ever biomarker for cisplatin.
Our patented DRP® analyzes 205 key genes in a patient’s tumor to predict their response to cisplatin and carboplatin, enabling personalized treatment plans to oncology patients. We have shown that our innovative technology not only improves survival rates, but also enables doctors to avoid overtreatment of toxic platin to non-responsding patients.
LiPlaCis®
A new formulation of cisplatin in a liposome aimed for a solution to cisplatin treatment by targeting tumors directly, reducing harmful side effects. Using a specialized liposome delivery system, LiPlaCis® releases cisplatin precisely where it's needed most—at the tumor site—providing safer and more effective cancer care.
Key Opinion Leaders
We’re honored by the strong support of seven prominent Key Opinion Leaders (KOLs) in the fields of lung, breast, bladder, and endometrial cancer. Their endorsement enhances the credibility of our DRP® and advances our mission toward precision oncology.
“We need to figure out how to select the right treatment to the right patients. So that is where the future goes. We are leaving the concept of one size fits all.”
Dr. Fred Hirsch